c-myc, p53 and bcl-2, apoptosis-related genes in infiltrating breast carcinomas: Evidence of a link between bcl-2 protein over-expression and a lower risk of metastasis and death in operable patients

International Journal of Cancer

Volumn 84, Issue 6, 1999, Pages 562-567

  Lê, Monique G ^a   Mathieu, Marie Christine ^a   Douc Rasy, Setha ^a   Le Bihan, Marie Luce ^a   Adb El All, Howayda ^a   Spielmann, Marc ^a   Riou, Guy ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; MYC PROTEIN; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53;

ADULT; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER MORTALITY; CANCER RECURRENCE; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; ONCOGENE C MYC; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK;

EID: 0032795072     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19991222)84:6<562::AID-IJC4>3.3.CO;2-S     Document Type: Article

References (23)

1. BARBARESCHI, M. and 12 OTHERS, bcl-2 and p53 expression in node-negative breast carcinoma: a study with long-term follow-up. Hum. Pathol., 27, 1149-1155 (1996).
2. BERNS, E.M.J.J., KLIJN, J.G.M., SMID, M., VAN STAVEREN, I.L., LOOK, M.P., VAN PUTTEN, W.L.J. and FOEKENS, J.A., TP53 and myc gene alterations independently predict poor prognosis in breast cancer patients. Genes Chromosomes Cancer, 16, 170-179 (1996).
3. BINDER, C., MARX, D., OVERHOFF, R., BINDER, L., SCHAUER, A. and HIDDEMANN, W., bcl-2 protein expression in breast cancer in relation to established prognostic factors and other clinicopathological variables. Ann. Oncol., 6, 1005-1010 (1995).
4. CHARPIN, C., GARCIA, S., BONNIER, P., MARTINI, F., ANDRAC, L., HORSCHOWSKI, N., LAVAUT, M.N. and ALLESIA, C., bcl-2 automated and quantitative immunocytochemical assays in breast cancer carcinomas: correlation with 10-year follow-up. J. clin. Oncol., 16, 2025-2031 (1998).
5. CONTESSO, G., MOURIESSE, H., FRIEDMAN, S., GENIN, J., SARRAZIN, D. and ROUËSSE, J., The importance of histologic grade in long-term prognosis of breast cancer: a study of 1,010 patients uniformly treated at the Institut Gustave-Roussy. J. clin. Oncol., 5, 1378-1386 (1987).
6. CLARK, G.M., Should selection of adjuvant chemotherapy for patients with breast cancer be based on erbB-2 status? J. nat. Cancer Inst., 90, 1320-1321 (1998).
7. ELLEDGE, R.M. and ALLRED, D.C., The p53 tumor suppressor gene in breast cancer. Breast Cancer Res. Treat., 32, 39-47 (1994).
8. EVAN, G.I., BROWN, L., WHYTE, M. and HARRINGTON, E., Apoptosis and the cell cycle. Curr. Opin. Cell Biol., 7, 825-834 (1995).
9. GASPARINI, G., BARBARESCHI, M., DOGLIONI, C., DALLA PALMA, P., MAURI, F.A., BORRACCHI, P., BEVILACQUA, P., CAFFO, O., MORELLI, L., VERDERIO, P., PEZZELLA, F. and HARRIS A.L., Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin. Cancer Res., 1, 189-198 (1995).
10. GUÉRIN, M., BARROIS, M., TERRIER, M.J., SPIELMANN, M. and RIOU, G., Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis. Oncogene Res., 3, 21-31 (1988).
11. HELLEMANS, P., VAN DAM, P.A., WEYLER, J., VAN OOSTEROM, A.T., BUYTAERT, P. and VAN MARCK, E., Prognostic value of bcl-2 expression in invasive breast cancer. Brit. J. Cancer, 72, 354-360 (1995).
12. JOENSUU, H., PYLKKÄNEN, L. and TOIKKANEN, S., bcl-2 protein expression and long-term survival in breast cancer. Amer. J. Pathol., 145, 1191-1198 (1994).
13. LEVINE, A.J., p53, the cellular gatekeeper for growth and division. Cell, 88, 323-331 (1997).
14. MOLL, U.M., RIOU, G. and LEVINE, A.J., Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc. nat. Acad. Sci. (Wash.),. 89, 7262-7266 (1992).
15. NASS, S.J. and DICKSON, R.B., Defining a role for c-myc in breast tumorigenesis. Breast Cancer Res. Treat., 44, 1-22 (1997).
16. OZBUN, M.A. and BUTEL, J.S., Tumor suppressor p53 mutations and breast cancer: a critical analysis. Adv. Cancer Res., 66, 71-141 (1995).
17. PEDUZZI, P., CONCATO, J., FEINSTEIN, A.R. and HOLFORD, T.R., Importance of events per independent variable in proportional hazards regression analysis. Accuracy and precision of regression estimates. J. clin. Epidemiol., 48, 1503-1510 (1995).
18. REED, J.C., bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Sem. Hematol., 4 (Suppl. 5), 9-19 (1997).
19. RYAN, J.J., PROCHOWNIK, E., GOTTLIEB, C.A., APEL, I.J., MERINO, R., NUNEZ, G. and CLARK, M.F., c-myc and bcl-2 modulate p53 function by altering p53 subcellular trafficking during the cell cycle. Proc. nat. Acad. Sci. (Wash.). 91, 5878-5882 (1994).
20. SILVESTRINI, R., BENINI, E., VENERONI, S., DAIDONE, M.G., TOMASIC, G., SQUICCIARINI, P. and SALVADORI, B., p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J. clin. Oncol., 14, 1604-1610 (1996).
21. SILVESTRINI, R., VENERONI, S., DAIDONE, M.G., BENINI, E., BORACCHI, P., MEZZETTI, M., DI FRONZO, G., RILKE, F. and VERONESI, U., The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J. nat. Cancer Inst., 86, 499-504 (1994).
22. SJÖGREN, S., INGANÄS, M., NORBERG, T., LINDGREN, A., NORDGREN, H., HOLMBERG, L. and BERGH, J., The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunochemistry. J. nat. Cancer Inst., 88, 173-182 (1996).
23. VAN SLOOTEN, H.J., CLAHSEN, P.C., VAN DIERENDONCK, J.H., DUVAL, C.H., PALLUD, C., MANDARD, A.M., DELOBELLE-DEROIDE, A., VAN DE VELDE, C.J.H. and VAN DE VIJVER, M.J., Expression of bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy. Brit. J. Cancer, 74, 78-85 (1996).